Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

 
 
FURTHER INFORMATION
 
 
 

Related Product News


NOW Diagnostics Acquires CELLMIC Reader Technology

Product News

Strengthens rapid diagnostics and point-of-care testing capabilities.

READ MORE

Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for the Selective Analysis of Tumor-Derived DNA and RNA

Product News

Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy